Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors

BACKGROUND: DNA electroporation has been demonstrated in preclinical models to be a promising strategy to improve cancer immunity, especially when combined with other genetic vaccines in heterologous prime-boost protocols. We report the results of 2 multicenter phase 1 trials involving adult cancer...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Diaz, Claudia Marcela, Chiappori, Alberto, Aurisicchio, Luigi, Bagchi, Ansuman, Clark, Jason, Dubey, Sheri, Fridman, Arthur, Fabregas, Jesus C, Marshall, John, Scarselli, Elisa, La Monica, Nicola, Ciliberto, Gennaro, Montero, Alberto J
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2013
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3599587/
https://ncbi.nlm.nih.gov/pubmed/23497415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-62
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars